| HOME >> MEDICINE >> TECHNOLOGY |
INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING 117
APPROVED PATENT ANALYSIS 117
TABLE 49 ANNUAL PATENTS FILED AND APPROVED WITH
BIOMARKER CLAIMS IN US, EUROPE, JAPAN, THROUGH 2010 118
COMPETITIVE LANDSCAPE 118
LATE STAGE CLINICAL TRIALS: COMPETITIVE
POSITIONING 118
TABLE 50 CURRENT GLOBAL MARKET FOR TOTAL CLINICAL
STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH
2010 ($ MILLIONS) 119
TABLE 51 GLOBAL MARKET FORECAST FOR CLINICAL STAGE
BIOMARKERS, THROUGH 2015 ($ MILLIONS) 120
APPLICATION BY THERAPY AREA 120
TABLE 52 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER
DELIVERY 120
TABLE 52 (CONTINUED) 121
TABLE 53 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS
BY THERAPEUTIC AREA, THROUGH 2010 ($ MILLIONS) 121
Oncology 121
TABLE 54 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:
ONCOLOGY 122
Cardiovascular 122
TABLE 55 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:
CARDIOVASCULAR 123
Central Nervous System 123
TABLE 56 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS
DISEASE 124
Immunology 124
TABLE 57 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:
IMMUNOLOGY 125
REPRESENTATIVE EXAMPLES WITHIN CANCER AND
IMMUNOLOGY 125
Cancer 125
Elesclomol: Synta 125
Immunology 126
Benlysta: Human Genome Sciences 126
Cancer 126
Hereptin: Roche 126
Expedition and Identity 126
Alzheimer's Trial: Eli Lilly 126
LEADING COMPANIES 127
AFFYMETRIX, INC 127
Company Overview 127
Products and Services 127
Company Strategy 127
BANYAN BIOMARKERS, INC 128
Company Overview 128
Products and Services 128
Company Strategy 128
BG MEDICINE, INC 129
Company Overview 129
Products and Services 129
Company Strategy 129
BI
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |